SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-028936
Filing Date
2022-11-08
Accepted
2022-11-08 16:23:06
Documents
15
Period of Report
2022-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20221104.htm   iXBRL 8-K 45526
2 EX-99.1 exhibit991-q32022.htm EX-99.1 98350
3 EX-99.2 exhibit992-q32022.htm EX-99.2 13176
7 GRAPHIC miratilogo2020.jpg GRAPHIC 11205
  Complete submission text file 0001628280-22-028936.txt   324707

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20221104.xsd EX-101.SCH 1897
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20221104_lab.xml EX-101.LAB 24137
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20221104_pre.xml EX-101.PRE 12508
9 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20221104_htm.xml XML 10551
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 221369254
SIC: 2834 Pharmaceutical Preparations